Warning: session_start(): Cannot send session cookie - headers already sent by (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1

Warning: session_start(): Cannot send session cache limiter - headers already sent (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1
OBR Daily - Our Oncology Focused E-News Service

Register for OBR daily

Warning: Missing argument 1 for showSidebarBanner(), called in /home2/don/public_html/sidebar_obrgreen.php on line 38 and defined in /home2/don/public_html/include/banners.php on line 243

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IDRA $2.80 0.2100 +8.11%
NKTR $15.93 0.9500 +6.34%
CRIS $1.43 0.0700 +5.15%
BCRX $11.16 0.5400 +5.08%
ARQL $1.29 0.0600 +4.88%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PARD $0.15 -0.0500 -25.00%
GERN $3.59 -0.2500 -6.51%
FATE $3.76 -0.2300 -5.76%
ARWR $5.84 -0.3250 -5.27%
THLD $2.90 -0.1300 -4.29%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

J&J Wins U.S. Approval For Hepatitis C Combo With Gilead

(Bloomberg) Nov 6, 2014 - Johnson & Johnson won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc.’s Sovaldi, making it the second all-oral treatment available for the most common form of the virus.
read article 

SGR and Health Reform Action Likely in New Congress

(MedPage Today) Nov 5, 2014 - The Affordable Care Act, the sustainable growth rate (SGR) formula for physician reimbursement under Medicare, and reauthorization of the Children's Health Insurance Program (CHIP) are all likely targets for action in the new Republican-controlled Congress, several health policy experts said Wednesday.
read article (free registration required) 

“Don’t Guess. Test.” Campaign Aims to Educate Patients About Comprehensive Genomic Testing in Lung Cancer

(CNBC) Nov 6, 2014 - The Bonnie J. Addario Lung Cancer Foundation (ALCF), in collaboration with Foundation Medicine and Friends of Cancer Research, and in partnership with many advocacy organizations, today launched the “Don’t Guess. Test.”
read article 

ASCO Holds Research Summit on Obesity and Cancer

(ASCO in Action) Nov 4, 2014 - The American Society of Clinical Oncology (ASCO) today convened its first-ever research summit to discuss challenges and opportunities in obesity and cancer research with representatives from many leading U.S. research institutions, cancer centers, and other organizations and federal agencies.
read article 

Medicare Releases Physician and Outpatient Payment Rules For 2015 – What Does It Mean For Hematology?

(ASH) Nov 5, 2014 - On October 31, 2014 at 4:15PM, the Centers for Medicare and Medicaid Services (CMS) released rules that detail payments and associated policies for services performed by physicians and those performed in the outpatient hospital setting.
read article 

BIND Therapeutics Announces Agreement With Merck to Develop Targeted Accurin™ Nanomedicines For Oncology

(CNBC) Nov 6, 2014 - BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology.
read article 

Google to Offer Foundation Medicine's Cancer Tests as Latest Health Benefit

(Reuters) Nov 5, 2014 - Google will soon start covering the cost of Foundation Medicine's DNA tests for employees and their family members suffering from cancer, as part of its health benefits portfolio.
read article 

California Hospital Explores Genetics-Aided Cancer Treatment

(Reuters) Nov 5, 2014 - A major California university hospital is exploring ways to gather and use genetic information gathered from cancer patients, hoping to break new ground in a fledgling field of genomic medicine.
read article 

Glaxo Scientists Work to Rebuild Cancer Line-Up, Funding Uncertain

(Reuters) Nov 5, 2014 - When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals.
read article 

Advaxis Files IND Application to FDA For Prostate Cancer Drug ADXS31-142

(Pharmaceutical Business Review) Nov 6, 2014 - US-based biotechnology firm Advaxis has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to conduct the first-in-human trial of ADXS31-142 to treat metastatic castration resistant prostate cancer (mCRPC).
read article 

First Guidelines on Integrative Therapy in Breast Cancer

(Medscape Medical News) Nov 6, 2014 - Even though the majority of breast cancer patients in the United States use complementary therapies, there has been a lack of evidence-based resources to help guide both clinicians and patients about their safety and effectiveness.
read article (free registration required) 

FDA Approves Ramucirumab For Advanced Gastric or GE Junction Adenocarcinoma

(ASCO in Action) Nov 5, 2014 - On November 5, 2014, the U. S. Food and Drug Administration approved ramucirumab (Cyramza®, Eli Lilly and Company) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
read article 

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline

(TheStreet) Nov 5, 2014 - Perhaps the biggest catalyst coming up is the presentation of Xtandi breast cancer data at the San Antonio Breast Cancer Symposium, December 9-13.
read article 

Celldex Therapeutics Shares Fall on Breast Cancer Study Changes

(TheStreet) Nov 5, 2014 - Investors are punishing Celldex Therapeutics today because of significant changes made to a phase III breast cancer study.
read article 

Epizyme Shares Weak on Disappointing Leukemia Drug Study Results

(TheStreet) Nov 6, 2014 - New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.
read article 

Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma

(Yahoo! Finance) Nov 6, 2014 - Exelixis, Inc. today announced that the enrollment target of 650 patients has been reached for METEOR, the company’s phase 3 pivotal trial of cabozantinib in patients with metastatic renal cell carcinoma (RCC) who have experienced disease progression following treatment with at least one VEGFR tyrosine kinase inhibitor (TKI).
read article 

Bone Drug Should Be Seen In a New Light For Its Anti-Cancer Properties

(Garvan Institute of Medical Research [Sydney, Australia]) Nov 6, 2014 - Australian researchers have shown why calcium-binding drugs commonly used to treat people with osteoporosis, or with late-stage cancers that have spread to bone, may also benefit patients with tumours outside the skeleton, including breast cancer.
read press release 

Risk Stratification Model May Aid in Lung Cancer Staging and Treatment Decisions

(IASLC) Nov 5, 2014 - A risk stratification model based on lymph node characteristics confirms with a high level of confidence the true lack of lung cancer in lymph nodes adequately sampled with endobronchial ultrasound-guided transbronchial needle aspiration and classified as negative.
read press release 

CT Lung Screening Appears Cost-Effective

(Brown University) Nov 5, 2014 – A new statistical analysis of results from the National Lung Screening Trial (NLST) concludes that performing low-dose computerized tomography screening can be cost-effective compared to doing no screening for lung cancer in aging smokers.
read press release 

Study Points to Overdiagnosis of Thyroid Cancer

(New York Times) Nov 5, 2014 - To the shock of many cancer experts, the most common cancer in South Korea is not lung or breast or colon or prostate.
read article 

Colon Cancers May Be Increasing Among Young Adults

(Reuters Health) Nov 5, 2014 - New diagnoses of colon and rectal cancers are on the rise among young adults while the numbers are falling among people who are older, according to a new study.
read article 

Genmab Announces Additional Data From Phase III Study of Ofatumumab as Maintenance Therapy For Relapsed CLL

(Yahoo! Finance) Nov 6, 2014 - 13.4 month improvement in median progression free survival in patients receiving ofatumumab maintenance therapy for relapsed CLL; data to be presented in oral session at ASH Annual Meeting in December.
read article 

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to Be Presented For the First Time

(Merck) Nov 6, 2014 - Merck, known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – the company’s anti-PD-1 therapy – in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC).
read corporate press release 

After A Long Year, An Update on Geron's Myelofibrosis Drug Is Disclosed

(TheStreet) Nov 6, 2014 - Updated results from a small study of Geron's experimental myelofibrosis drug imetelstat disclosed Thursday yielded a remission rate of 21%, essentially unchanged from results presented one year ago, with significant side effects.
read article 

Novartis Announces Outcome of FDA Advisory Committee Meeting For Multiple Myeloma Investigational Compound LBH589

(Novartis) Nov 6, 2014 - Novartis announced today that the US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not recommend the investigational compound LBH589 (panobinostat), a pan-deacetylase (pan-DAC) inhibitor, for patients with previously treated multiple myeloma when used in combination with bortezomib[*] and dexamethasone.
read corporate press release